A phase II trial also demonstrated that apatinib possessed a potential clinical activity without paralleling additional toxicity in advanced NSCLC cases who suffered from at least two front‐line therapies including the standard of care by EGFR‐TKIs.25 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.